A Phase I Open Label Study Of Panobinostat In Combination With Lenalidomide, Bortezomib, And Dexamethasone In Patients With Relapsed And Relapsed/Refractory Multiple Myeloma
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 01 Feb 2017
At a glance
- Drugs Panobinostat (Primary) ; Bortezomib; Dexamethasone; Lenalidomide
- Indications Multiple myeloma
- Focus Adverse reactions
- Acronyms PanRVD
- 24 Jan 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Dec 2017.
- 24 Jan 2017 Status changed from recruiting to active, no longer recruiting.
- 07 Jun 2016 Interim results (n=16) presented at the 52nd Annual Meeting of the American Society of Clinical Oncology